JUPITER, Fla., April 25, 2017 /PRNewswire/ -- Jupiter Orphan Therapeutics, Inc. (JOT) today announced that they have partnered with Canadian company InSymbiosis. Insymbiosis will assist JOT with managing its clinical trial manufacturing and supplying. It will also assist in the upcoming PK/PD studies in Canada.
"This agreement is in line with JOT's philosophy of staying virtual and outsourcing specific projects to experts in the field," stated JOT CEO, Christer Rosén.
"We are very excited to initiate our clinical development program in collaboration with InSymbiosis," stated JOT CSO, Marshall Hayward, Ph.D.
"Supporting JOT's CMC and clinical activities is exactly in line with our desire to help virtual drug development companies advance their programs and thereby enable new medications to get to patients faster," stated InSymbiosis' CEO, Dean Wenham, Ph.D.
Founded in 2005 and managed by seasoned ex-pharma/CRO drug development scientists and executives, InSymbiosis is committed to improving how biopharma companies outsource drug development R&D. By investing in their innovative infrastructure and processes, they have built a dynamic and powerful platform enabling their partners to cost effectively outsource drug development activities via InSymbiosis' general contractor model whilst benefiting from InSymbiosis' vast drug development and program management experience. Based in Montreal, Canada, InSymbiosis' team is comprised of a multidisciplinary drug development group, quality professionals, financial and investment experts, and a strong business development and CRO procurement team.